C. Rossetto

Platinum-Based Chemotherapy in Older Patients with Non-Small Cell Lung Cancer: What to Expect in the Real World

G. Fasola, F. Puglisi, M. Macerelli, 2020, Drugs & Aging.

Prognostic Stratification of Stage IIIA pN2 Non-small Cell Lung Cancer by Hierarchical Clustering Analysis of Tissue Microarray Immunostaining Data: An Alpe Adria Thoracic Oncology Multidisciplinary Group Study (ATOM 014)

R. Spizzo, G. Fasola, O. Belvedere, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase II study of irinotecan and docetaxel in patients with previously treated non-small cell lung cancer: an Alpe-Adria Thoracic Oncology Multidisciplinary group study (ATOM 007).

R. Spizzo, G. Fasola, O. Belvedere, 2006, Lung cancer.

Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II–III trial

R. Orecchia, A. Paccagnella, C. Casanova, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Concomitant chemoradiation (CRT) or cetuximab/RT (CET/RT) versus induction Docetaxel/ Cisplatin/5-Fluorouracil (TPF) followed by CRT or CET/RT in patients with Locally Advanced Squamous Cell Carcinoma of Head and Neck (LASCCHN). A randomized phase III factorial study (NCT01086826).

I. Floriani, A. Paccagnella, G. Azzarello, 2014 .

A randomised phase II study of docetaxel/oxaliplatin and docetaxel in patients with previously treated non-small cell lung cancer: an Alpe-Adria Thoracic Oncology Multidisciplinary group trial (ATOM 019).

G. Fasola, O. Belvedere, S. Meduri, 2011, European journal of cancer.

Cetuximab/radiotherapy (CET+RT) versus concomitant chemoradiotherapy (cCHT+RT) with or without induction docetaxel/cisplatin/5-fluorouracil (TPF) in locally advanced head and neck squamous cell carcinoma (LASCCHN): Preliminary results on toxicity of a randomized, 2x2 factorial, phase II-III study (N

L. Crinò, I. Floriani, A. Paccagnella, 2012 .

Bone metastases from head and neck malignancies: Prognostic factors and skeletal-related events

P. Conte, C. Resteghini, M. Merlano, 2019, PloS one.

1312P Prognostic impact of KRAS status in patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitor monotherapy

G. Fasola, A. Fantin, A. Follador, 2021, Annals of Oncology.

Nasopharyngeal cancer in non-endemic areas: Impact of treatment intensity within a large retrospective multicentre cohort.

A. Argiris, I. Garassino, A. Trama, 2021, European journal of cancer.

A phase II-III study comparing concomitant chemoradiotherapy (CRT) versus cetuximab/RT (CET/RT) with or without induction docetaxel/cisplatin/5-fluorouracil (TPF) in locally advanced head and neck squamous cell carcinoma (LASCCHN): Efficacy results (NCT01086826).

L. Crinò, I. Floriani, A. Paccagnella, 2013 .